GRAIL Galleri Test Advances at FDA; PAMA Cuts Threaten Lab Margins

GRAIL Galleri Test Advances at FDA; PAMA Cuts Threaten Lab Margins In this episode, we discuss two major developments affecting laboratory medicine: GRAIL's Galleri multi-cancer early detection test moving closer to FDA approval, and proposed Medicare reimbursement cuts that could significantly impact clinical laboratories.

We begin with the FDA advisory committee's recent review of Galleri, which received a unanimous 10–0 vote on safety but a narrower 6–4 vote on effectiveness. Despite this progress, questions remain about the test's clinical utility, particularly its relatively low sensitivity for early-stage cancers and its failure to meet the trial's primary endpoint.

We also discuss advances in Alzheimer's disease blood biomarkers, including p-tau217 testing, and the challenges laboratories face in interpreting results across different patient populations.

Finally, we examine newly released CMS data under the Protecting Access to Medicare Act (PAMA), which proposes substantial reductions in clinical laboratory reimbursement beginning in 2027. We consider what these cuts could mean for independent laboratories, industry consolidation, and access to laboratory services in rural communities.

Topics Discussed

GRAIL Galleri and FDA approval: The advisory committee voted 10–0 on safety and 6–4 on effectiveness. However, Galleri demonstrated only 21% sensitivity for stage 1 cancers and 35% overall sensitivity. The trial did not meet its primary endpoint of reducing stage 3 and 4 cancer diagnoses, although stage 4 cancers decreased by 14%. Alzheimer's blood biomarker testing: Emerging p-tau217 assays from Fujirebio, Roche, and C2N Diagnostics have demonstrated sensitivities of approximately 95–99% in memory-clinic populations. We discuss whether these results will translate to broader primary care settings. The importance of clinical interpretation: As new screening and diagnostic technologies become more widely available, laboratories may need to play a larger role in helping clinicians understand results in the context of patient age, symptoms, and pretest probability. Proposed PAMA reimbursement reductions: Preliminary 2027 Medicare payment rates would reduce reimbursement for 1,171 of approximately 1,500 laboratory fee schedule codes. Average proposed reductions include 22% for molecular pathology, 16% for chemistry, and 23% for genomic sequencing. Industry response and laboratory consolidation: Labcorp and Quest Diagnostics are challenging the proposed reductions. We discuss how continued reimbursement pressure could accelerate consolidation and threaten the financial viability of smaller and independent laboratories. Rural laboratory access: We explore the potential consequences of reimbursement reductions for rural communities and preview our ongoing research examining access to laboratory services.

GRAIL Galleri Test Advances at FDA; PAMA Cuts Threaten Lab Margins

In this episode, we discuss two major developments affecting laboratory medicine: GRAIL's Galleri multi-cancer early detection test moving closer to FDA approval, and proposed Medicare reimbursement cuts that could significantly impact clinical laboratories.

We begin with the FDA advisory committee's recent review of Galleri, which received a unanimous 10–0 vote on safety but a narrower 6–4 vote on effectiveness. Despite this progress, questions remain about the test's clinical utility, particularly its relatively low sensitivity for early-stage cancers and its failure to meet the trial's primary endpoint.

We also discuss advances in Alzheimer's disease blood biomarkers, including p-tau217 testing, and the challenges laboratories face in interpreting results across different patient populations.

Finally, we examine newly released CMS data under the Protecting Access to Medicare Act (PAMA), which proposes substantial reductions in clinical laboratory reimbursement beginning in 2027. We consider what these cuts could mean for independent laboratories, industry consolidation, and access to laboratory services in rural communities.

Topics Discussed

• GRAIL Galleri and FDA approval: The advisory committee voted 10–0 on safety and 6–4 on effectiveness. However, Galleri demonstrated only 21% sensitivity for stage 1 cancers and 35% overall sensitivity. The trial did not meet its primary endpoint of reducing stage 3 and 4 cancer diagnoses, although stage 4 cancers decreased by 14%.
• Alzheimer's blood biomarker testing: Emerging p-tau217 assays from Fujirebio, Roche, and C2N Diagnostics have demonstrated sensitivities of approximately 95–99% in memory-clinic populations. We discuss whether these results will translate to broader primary care settings.
• The importance of clinical interpretation: As new screening and diagnostic technologies become more widely available, laboratories may need to play a larger role in helping clinicians understand results in the context of patient age, symptoms, and pretest probability.
• Proposed PAMA reimbursement reductions: Preliminary 2027 Medicare payment rates would reduce reimbursement for 1,171 of approximately 1,500 laboratory fee schedule codes. Average proposed reductions include 22% for molecular pathology, 16% for chemistry, and 23% for genomic sequencing.
• Industry response and laboratory consolidation: Labcorp and Quest Diagnostics are challenging the proposed reductions. We discuss how continued reimbursement pressure could accelerate consolidation and threaten the financial viability of smaller and independent laboratories.
• Rural laboratory access: We explore the potential consequences of reimbursement reductions for rural communities and preview our ongoing research examining access to laboratory services.